May 2021 - Page 2 of 6 - BioMedWire (BMW)

MondayMay 24, 2021 1:51 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Upcoming Drug Candidate Trial Rides Swell of Groundbreaking Psychedelic Medicine Efforts

Tryp Therapeutics is a pharmaceutical company focused on developing new potential treatments for medical conditions with unmet needs The company’s current lead candidates for drug development are a synthetic psychedelic for treating fibromyalgia and eating disorders Tryp’s efforts to develop a psychedelic drug candidate are part of a broader scientific movement to use various mind-altering drugs to treat select neurological conditions when paired with the care of a trained therapist The company has been preparing to initiate a Phase 2a clinical trial for the psychedelic candidate in partnership with a medical research team at the University of Florida The idea…

MondayMay 24, 2021 11:45 am

University of Washington Study Suggests Coronavirus Fatalities May Be Higher Than Official Reports Have Indicated

Researchers from the Institute for Health Metrics and Evaluation (“IHME”) at the University of Washington have discovered evidence suggesting that the number of individuals who have succumbed to the coronavirus is higher than official reports have indicated. The team performed an analysis on fatalities caused by the coronavirus and reported its findings on the IHME website. Many physicians involved in the fight against the pandemic agree that the number of individuals who have succumbed to this fatal disease is higher than official reports have shown. The discrepancy in numbers is mainly because many individuals who died weren’t listed as coronavirus…

FridayMay 21, 2021 2:00 pm

Study Finds That Mental Health is Essential in Recovery from Cardiac Events

Recent research that was presented at the 70th Annual Scientific Session, which is held by the American College of Cardiology, has found that middle-aged and young adults who have been diagnosed with conditions such as anxiety or depression after they’ve suffered cardiac arrest have twice a higher chance of suffering from a second heart attack when compared with individuals who experience mild levels of distress. Researchers noted that the study evaluates how mental health impacts the outlook for cardiac arrest survivors. They added that they also tracked inflammatory markers that may contribute to an increased risk of cardiovascular diseases among…

FridayMay 21, 2021 9:15 am

Brain Scientific Inc. (BRSF) Committed to Expand Access to Neurological Care for Infected Patients Amid the Pandemic

Consequences of novel Coronavirus infection on brain health are significant, requiring frequent brain monitoring Brain diagnostics in infected patients extremely limited due to their severe physical illnesses; traditional EEG time consuming, exposes frontline workers to virus transmission risk BRSF's sanitary disposable NeuroCap(TM) helps health care workers get quick, reliable insights into patient's condition while minimizing cross-contamination risk Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company providing next-gen solutions to the neurology market, is poised to offer a response to brain diagnostic challenges in the hospitals' red zones amid the pandemic. As the Company describes in one of the recent articles…

ThursdayMay 20, 2021 1:00 pm

New Technique Promises to Deliver Cancer Drugs More Effectively

A University of Massachusetts team has created a nanoparticle that could potentially transform the way different diseases, including cancer, are treated. The approach combines two methods that allow medicine to be delivered to targeted cells more effectively. At the moment, one of the best new ways to deliver anti-cancer medicine is by using biologics (i.e., protein-based medications). The major benefits of this method are that the biologics have the capacity to replace proteins that have malfunctioned within a cell, and these drugs have minimal adverse side effects. The chief downside of biologics is that the particles are large, which limits…

ThursdayMay 20, 2021 9:00 am

Brain Scientific Inc. (BRSF) Offers Solutions for COVID-19 EEG Accessibility

Seizures have been common in hospitalized COVID-19 patients, and the death rate higher in those who experienced the seizures Due to a shortage of PPE and limited contact, EEG accessibility was limited during the pandemic The NeuroCap can fill the gap in EEG accessibility during the pandemic and into the future, as more long-term studies are created Brain Scientific (OTCQB: BRSF) is developing innovative and proprietary medical devices and software to bridge the widening gap in access to quality care. The Company’s first commercialized devices, the NeuroCap(TM) and NeuroEEG(TM), offer cost-effective and disposable substitutes to their traditional counterparts. The NeuroCap…

WednesdayMay 19, 2021 11:14 am

New Study Links Neurodegenerative Diseases to Gut Bacteria Changes

New research done by a team from the University of Florida has uncovered evidence that links the manifestation of neurodegenerative diseases such as Parkinson’s, Alzheimer’s and ALS to the presence of specific bacteria types in the gut. Previous research had pointed to gut microbiota changes in people who suffered from neurodegenerative conditions. However, the huge diversity of bacteria in the digestive tract made it a daunting task to pinpoint the specific bacteria types connected to neurodegenerative diseases. This is the challenge that the University of Florida team took head on. Rather than study the gut microorganisms of humans, the researchers…

TuesdayMay 18, 2021 3:09 pm

Leukemia Treatment Could Lie in Avocado Compound

Like many other types of cancer, leukemia currently has no cure. Although treatments are largely dependent on whether the cancer is slow growing or aggressive, most of the treatments are pretty toxic and, in extreme cases, can even cost the patients their lives. There are several types of leukemia, and researchers from the University of Guelph may have found a way to cure one of the most devastating forms of cancer, acute myeloid leukemia (“AML”). AML often afflicts people over the age of 65 and has quite a low survival rate; less than 10% of patients live for more than…

TuesdayMay 18, 2021 1:46 pm

RYAH Group, Inc. (CSE: RYAH) Enters New Zealand Market

A partnership with Medical Kiwi LTD makes it possible for RYAH to enter the New Zealand Market Medical Kiwi was the first South Island-based company to be granted a Medicinal Cannabis license from the Ministry of Health to cultivate The potential market for medical cannabis in New Zealand is at NZ$1.5 billion RYAH Group (CSE: RYAH), a health care analytics and technology company, has entered the New Zealand market through a definitive wholesale supply and distribution agreement with Medical Kiwi LTD (https://ibn.fm/jN4T7). This agreement enables RYAH’s suite of IoT devices and cloud-based data analytics to be used in pre-clinical and…

TuesdayMay 18, 2021 1:30 pm

Predictive Oncology Inc. (NASDAQ: POAI) Appoints Venture Investor Dr. Christina Jenkins to Board of Directors

POAI appoints strategic advisor, venture investor Dr. Christina Jenkins to board of directors Dr. Jenkins’ experience spans work in capital markets, clinical medicine, public healthcare systems Other roles include current Board Director for Independence Health Group, Venture Partner at Phoenix Venture Partners, Board Observer for Madorra Inc., board advisory roles at multiple value-generating healthcare companies Past experience includes role as founding CEO of OneCity Health Services, subsidiary of NYC Health + Hospitals Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently appointed strategic advisor and venture investor Dr. Christina…